Latest Breast cancer classification Stories

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression — among them mutations, amplifications, substitutions, and translocations — have been found in 14 different advanced solid tumors. The results of the study of more than 2,000 tumors, being presented at the annual meeting of the American Society of Clinical Oncology (ASCO), both surprised researchers and provided hope that some of these...

CHICAGO and SEATTLE, June 1, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported on final results from a cooperative group and NCI-sponsored Phase 2 clinical trial of brostallicin in combination with cisplatin for the treatment of women with metastatic triple-negative breast cancer (mTNBC). Triple-negative breast cancer lacks progesterone and estrogen receptors and the HER2 biomarker that is present in most breast cancers, which makes standard...

-- Data suggest presence of activated progesterone receptors in cells predict anti-progestin efficacy in endometrial and breast cancers; support further evaluation of onapristone FLEMINGTON, N.J., May 15, 2013 /PRNewswire/ -- Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced new, positive data from three studies supporting its investigational compound onapristone to be presented at...

-Determining a breast-cancer patient’s prognosis can be difficult because breast tumors contain many genetic differences and there are many subtypes; -This study combined and analyzed large masses of data from 466 cases of the most common type of breast cancer; -The study identified a small group of molecules that might predict breast-cancer prognosis across many subtypes of the disease and at its early stages; -For the first time a prognostic signature in cancer is composed of both mRNA...

A team of international cancer researchers led by Dr. Mathieu Lupien at the Princess Margaret Cancer Centre, University Health Network, has identified the signalling pathway that is over-activated in estrogen receptor (ER)-positive breast cancer cells that are resistant to hormone therapies such as tamoxifen, aromatase inhibitors or fulvestrant. Resistance to hormone therapy is reported in almost half of ER-positive breast cancer patients and no cure is currently available. The fact that...

University of North Carolina Health Care Triple-negative breast cancers are more biologically diverse than previously believed and classification should be expanded to reflect this heterogeneity, according to University of North Carolina researchers. In a study published in the February issue of The Oncologist conducted by UNC and the Vall d'Hebron Institute of Oncology in Barcelona, Spain, a team lead by Charles Perou, PhD, of UNC Lineberger Comprehensive Cancer Center, examined more...

-Triple-negative breast cancer is an aggressive form of breast cancer that has few treatment options; -This large-scale study shows that abnormal levels of small molecules called microRNA can be used to classify this malignancy into four subtypes; -The findings could lead to new ways to identify the best therapy for individual patients and to more effective therapies in the future. A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be...

Lawrence LeBlond for redOrbit.com - Your Universe Online Health advocates for years have told us that milk does the body good. Health experts have also been keen on promoting the positive effects breastfed milk has on childhood development. But now, milk is getting a bad rap--particularly, a certain protein found in breast milk is the problem. Scientists have recently discovered that this protein, called ELF5, which is found in all breast cells and is responsible for milk production, is...

SEATTLE, Dec. 5, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported on interim results from a cooperative group sponsored Phase 2 clinical trial of brostallicin in combination with cisplatin for the treatment of women with metastatic triple-negative breast cancer that were presented at the San Antonio Breast Cancer Symposium (SABCS) held from December 4-8, 2012. The study enrolled women with confirmed measurable metastatic disease and triple...

SAN FRANCISCO, Nov. 5, 2012 /PRNewswire-USNewswire/ -- A unique formula made from medicinal mushrooms, traditional Chinese herbs and other natural ingredients inhibits aggressive, human triple-negative breast cancer and breast-to-lung metastasis in mice. This is the third peer-reviewed study to demonstrate the botanical formula's anticancer effects. The formula decreases metastasis, slows cancer growth and suppresses a number of pro-cancer genes, with no signs of toxicity....